Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

elated to proprietary taste science technologies.  

Financial Review:The Company has modified the presentation of its statements of operations.  Historically, commercial revenues have been presented net of related direct costs, which to date have been comprised of royalty payments related to certain in-licensed technologies.  Effective with these 2012 financial results and for previous periods to which these results are compared, the related direct costs will be reported as a component of operating expenses defined as cost of commercial revenues.  This modification does not have an impact on cash flow or net results.  The financial results described below reflect this modification.

Total revenues were $31.3 million for 2012 compared to $31.6 million for 2011.  Total revenues were $8.2 million for the fourth quarter of 2012 compared to $8.6 million for the fourth quarter of 2011.

Development revenues were $27.0 million in 2012 compared to $28.2 million in 2011.  Development revenues were $6.7 million in the fourth quarter of 2012 compared to $7.7 million in the fourth quarter of 2011.  The decrease in the fourth quarter is primarily due to lower upfront license fee revenues recognized in 2012 compared to 2011.  Specifically, the Company recognized approximately $200,000 and $900,000 in the fourth quarter of 2012 and 2011, respectively, related to the $20 million in license payments under the 2009 Sweet Program collaboration with Firmenich.  There was no impact to cash flow as the license payments were received prior to 2011.

Commercial revenues were $4.3 million for 2012 compared to $3.4 million for 2011.  Commercial revenues were $1.5 million for the fourth quarter of 2012 compared to $940,000 for the fourth quarter of 2011. These increases resulted from higher commercial revenues related to our Savory Taste and Sweet Taste programs, as well as royalties from sales relat
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, ... the U.S. Patent and Trademark Office (PTO) has issued ... being evaluated for weight loss. NB32 is a fixed-dose ... U.S. Patent No. 8,815,889 claims methods for ... bupropion. The patent expires in 2024. If NB32 is ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... 13 Proteon Therapeutics is,presenting new data ... potential of PRT-201 to enhance outcomes in ... (PAD). The,presentation, entitled, "Local Catheter-Directed Elastase Therapy: ... is being made at the 20th,annual Transcatheter ...
... CLARA, Calif., Oct. 13 WebLOQ, Inc., ... secure and compliant eBusiness and,data-in-motion communications, today ... the WebLOQ ePrivacy solution in their state-of-the-art,Monterey ... partner, the,Monterey Peninsula Surgery Center, and other ...
... SYDNEY, Australia, Oct. 13 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: ... Quarterly,Report to Shareholders on the afternoon of Wednesday ... teleconference the following morning to,review the quarter and ... on Thursday 16th October at 8.30am (Sydney),(Wednesday 15th ...
Cached Biology Technology:Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 3
(Date:9/2/2014)... may have discovered a new way of harnessing lupus ... DNA repair. , The findings were published recently in ... study, led by James E. Hansen, M.D., assistant professor ... that cancer cells with deficient DNA repair mechanisms (or ... significantly more vulnerable to attack by lupus antibodies. , ...
(Date:9/2/2014)... true that digital distribution of media will have ... at least when file sizes are large. , ... Yale,s Journal of Industrial Ecology that ... consoles such as PlayStation3. Researchers found that Blu-ray ... gas emissions than game files downloaded over broadband ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... theoretical price of having one's personal genome sequenced just ... $2.2 million, and the goal is to reduce the ... realistic. , The sharp drop is due to a ... (HMS) researchers Jay Shendure, Gregory Porreca, George Church, and ...
... form of a powerful painkiller for a quick and dangerous ... alarm as the number of people dying from an overdose ... than morphine, rises. , Addicts are misusing a clear patch ... into the bloodstream over the course of a few days, ...
... with a Global Information System will provide valuable information ... National Institute of Environmental Health Sciences (NIEHS), one of ... provide the most up-to-date data to public health and ... industry maps, as well as demographic information for local ...
Cached Biology News:A step toward the $1,000 personal genome using readily available lab equipment 2Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3FDA approves child-friendly AIDS medicine 2
... High-throughput protein crystallography involves using many ... Screening (HTS). The liquid handling requirements are ... volume: traditional crystallography plates have 24 or ... of microliters. For higher throughput, the number ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... designed for protein pull-down experiments ... binding proteins. An order of ... agarose beads with 10 nmol ... terminus of the alkyl chain; ...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
Biology Products: